Back to mobile site

Halozyme Therapeutics' (HALO) Price Target Raised to $21 at JMP

June 4, 2015 8:23 AM EDT Send to a Friend
JMP Securities maintained a Market Outperform rating on Halozyme Therapeutics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login